Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Elevance Health Inc.
ELV
NYSE·Healthcare·Medical - Healthcare Plans·Mkt cap $90.4B
$417.89
▲ +0.41%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$273.71 - $427.07
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 18.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive National Healthcare Network
- Advanced Digital Health Technology
- Comprehensive Care Ecosystem
- Strong Data Analytics Capabilities
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Telehealth Expansion
Value
Attractively priced below Managed Care & Health Insurance peer average
Momentum
Hot
+38.4% over 3m
Quality
Stable
Excellent business quality
Dividend
Modest
1.65% yield
Smart-money signal
Who's buying ELV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 20, 2026
APR 22, 2026
Reported EPS of $12.58 vs $11.03 consensus (+14.1% surprise). Revenue of $49.5B vs $48.2B expected (+2.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+14.1%
Next: Apr 20, 2026
Revenue trend · last 8Q
—
—
+7%
+15%
+14%
+12%
+9%
+3%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$43.6B
$45.1B
$45.4B
$48.9B
$49.8B
$50.7B
$49.7B
$50.2B
Margins · last 8Q
Gross
18.1%
Operating
5.3%
Profit
3.5%
Wall Street consensus
14 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
$421.50
▲ +0.9% vs $417.89
Latest: Bernstein · Jul 2, 2026
9 analysts covering